Scientists test new drug cocktail in fight against tough pancreatic cancer
NCT ID NCT01660971
Summary
This early-stage study is testing a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in patients with advanced pancreatic cancer that has spread or cannot be surgically removed. The main goals are to find the safest and most effective dose and to understand the side effects. Researchers hope this combination will work together to stop cancer cell growth better than single drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.